I agree that this site is using cookies. You can find further informations here.
X
Ihle, Michaela Angelika
50  results:
Search for persons X
?
1

Biomarker MET in tumor pathology; Biomarker MET in der Tumo..:

Ihle, Michaela Angelika ; Heydt, Carina
Die Pathologie.  44 (2023)  3 - p. 193-196 , 2023
Link: https://doi.org/10.1007/..
 
?
2

Overview of Molecular Detection Technologies for MET in Lun..:

Heydt, Carina ; Ihle, Michaela Angelika ; Merkelbach-Bruse, Sabine
Cancers.  15 (2023)  11 - p. 2932 , 2023
Link: https://doi.org/10.3390/..
 
?
3

Mutational spectrum of acquired resistance to reversible ve..:

Wagener-Ryczek, Svenja ; Heydt, Carina ; Süptitz, Juliane...
BMC Cancer.  20 (2020)  1 - p. , 2020
Link: https://doi.org/10.1186/..
 
?
4

Expression of cell cycle regulators and frequency of TP53 m..:

Ihle, Michaela Angelika ; Huss, Sebastian ; Jeske, Wiebke...
PLOS ONE.  13 (2018)  2 - p. e0193048 , 2018
Link: https://doi.org/10.1371/..
 
?
5

EGFR T790M mutation testing of non-small cell lung cancer t..:

Fassunke, Jana ; Ihle, Michaela Angelika ; Lenze, Dido...
Virchows Archiv.  471 (2017)  4 - p. 509-520 , 2017
Link: https://doi.org/10.1007/..
 
?
6

Copy number variations in atypical fibroxanthomas and pleom..:

Helbig, Doris ; Quaas, Alexander ; Mauch, Cornelia...
Oncotarget.  8 (2017)  65 - p. 109457-109467 , 2017
Link: https://doi.org/10.18632..
 
?
7

Clinicopathological and molecular features of a large cohor..:

Huss, Sebastian ; Pasternack, Helen ; Ihle, Michaela Angelika...
Human Pathology.  62 (2017)  - p. 206-214 , 2017
Link: https://doi.org/10.1016/..
 
?
8

Oncogene and therapeutic target analyses in atypical fibrox..:

Helbig, Doris ; Ihle, Michaela Angelika ; Pütz, Katharina...
Oncotarget.  7 (2016)  16 - p. 21763-21774 , 2016
Link: https://doi.org/10.18632..
 
?
9

Massively parallel sequencing fails to detect minor resista..:

Heydt, Carina ; Kumm, Niklas ; Fassunke, Jana...
BMC Cancer.  15 (2015)  1 - p. , 2015
Link: https://doi.org/10.1186/..
 
?
10

FGFR2 is overexpressed in myxoid liposarcoma and inhibition..:

Künstlinger, Helen ; Fassunke, Jana ; Schildhaus, Hans-Ulrich...
Oncotarget.  6 (2015)  24 - p. 20215-20230 , 2015
Link: https://doi.org/10.18632..
 
?
11

miRNA‐221 and miRNA‐222 induce apoptosis via the KIT/AKT si..:

Ihle, Michaela Angelika ; Trautmann, Marcel ; Kuenstlinger, Helen...
Molecular Oncology.  9 (2015)  7 - p. 1421-1433 , 2015
Link: https://doi.org/10.1016/..
 
?
12

Comparison of high resolution melting analysis, pyrosequenc..:

Ihle, Michaela Angelika ; Fassunke, Jana ; König, Katharina...
BMC Cancer.  14 (2014)  1 - p. , 2014
Link: https://doi.org/10.1186/..
 
?
13

Comparison of Pre-Analytical FFPE Sample Preparation Method..:

Heydt, Carina ; Fassunke, Jana ; Künstlinger, Helen...
PLoS ONE.  9 (2014)  8 - p. e104566 , 2014
Link: https://doi.org/10.1371/..
 
?
14

HR23b expression is a potential predictive biomarker for HD..:

Angelika Ihle, Michaela ; Merkelbach‐Bruse, Sabine ; Hartmann, Wolfgang...
The Journal of Pathology: Clinical Research.  2 (2016)  2 - p. 59-71 , 2016
Link: https://doi.org/10.1002/..
 
?
15

Mutational spectrum of acquired resistance to reversible ve..:

Wagener-Ryczek, Svenja ; Heydt, Carina ; Süptitz, Juliane...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216404/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
1-15